Documents on Display

The document that you are looking for has been removed by the listed issuer and is no longer available.

Blue Application Form

Green Application Form

Global Offering (Offer for Subscription)

Global Offering (Formal Notice)

China’s First Denosumab Biosimilar Boyoubei® Approved for Launch by NMPA

Shanghai, November 10, 2022 –Boan Biotech today announced that self-developed Denosumab Injection (Boyoubei®) has been approved for launch in China by the National Medical Products Administratio...

Boan Biotech’s BA2101 Injection Approved for Clinical Trials in China

October 27, 2022 -- Boan Biotech announced today that BA2101 has been approved by the Center for Drug Evaluation of the National Medical Products Administration for clinical trials in China. This is a...

Boan Biotech’s Broad-Spectrum Neutralizing Antibody BA-CovMab Injection Approved for Clinical Trials in China

Shanghai, September 12, 2022 –BA-CovMab injection, the broad-spectrum neutralizing antibody developed by Boan Biotech for use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Boan Biotech’s Investigational Anti-CD25 Antibody BA1106 Approved for the First Clinical Trial on Treating Solid Tumors in China

Shanghai, September 7, 2022 - Luye Pharma Group announced today that BA1106, a human anti-CD25 monoclonal antibody developed by its subsidiary Boan Biotech, has been approved for clinical trials by th...

Boan Biotech Starts Phase III Clinical Trial in China for Dulaglutide Injection (BA5101)

Luye Pharma Group announced on July 14 that its subsidiary Boan Biotech has started a Phase III clinical trial, which is a comparative clinical efficacy and safety study, for Dulaglutide Injection (BA...